Overall, our data clearly defines ALDH1A3 as a possible predictive factor of pro‐aggressiveness and could be used to predetermine tumor predisposition to acquire aggressive/invasive capacity in RCC patients treated with antiangiogenic therapies (Fig 7H). Here, ALDH1A3 is linked to renal cell carcinoma.